ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 37.25 |
| Open | 36.85 |
| Bid | 35.59 x 800 |
| Ask | 35.79 x 1300 |
| Day's Range | 35.48 - 36.96 |
| 52 Week Range | 27.85 - 54.45 |
| Volume | 201,446 |
| Avg. Volume | 581,067 |
| Market Cap | 1.647B |
| Beta (3Y Monthly) | 4.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.65 |
| Earnings Date | Nov 2, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.60 |
- American City Business Journals•14 days ago
At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
- GlobeNewswire•18 days ago
Atara Biotherapeutics to Participate in the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Zacks•18 days ago
Company News For Jan 4, 2019
Companies in the news are: BMY, CELG, DAL, TRCO and ATRA
- Motley Fool•19 days ago
Why Delta Air Lines, Atara Biotherapeutics, and Skyworks Solutions Slumped Today
Find out what made these high-flying stocks lose altitude.
- GlobeNewswire•19 days ago
Atara Biotherapeutics Announces Planned Chief Executive Officer Transition
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover, M.D., plans to step down as the Company’s President and Chief Executive Officer. Dr. Ciechanover will remain in his role as President and CEO until the earlier of the appointment of his successor or June 30, 2019. “Isaac is a visionary founder and CEO who started Atara in honor of his mother to transform the lives of patients with serious medical conditions,” said Carol G. Gallagher, Pharm.
- GlobeNewswire•19 days ago
Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy for Solid Tumors
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T.
- Insider Monkey•last month
Should You Avoid Atara Biotherapeutics Inc (ATRA)?
We can judge whether Atara Biotherapeutics Inc (NASDAQ:ATRA) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best […]
- GlobeNewswire•last month
Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)
Second EBV‑associated solid tumor with encouraging responses to tab-cel®Tab-cel® safety appears consistent with a favorable risk profile and previous observationsResults were.
- GlobeNewswire•2 months ago
Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•2 months ago
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that results of a Phase 1 clinical study conducted by the Company's collaborating investigators at QIMR Berghofer Medical Research Institute and The University of Queensland were published online in JCI Insight. The article describes clinical findings observed in progressive multiple sclerosis (MS) patients treated with ATA190, Atara’s autologous EBV-specific T-cell immunotherapy. “We previously presented promising initial ATA190 results in patients with progressive MS, and the published results confirm our earlier observations,” said Professors Michael Pender, The University of Queensland and Rajiv Khanna, Coordinator of QIMR Berghofer Centre for Immunotherapy and Vaccine Development.
- Associated Press•3 months ago
Atara Biotherapeutics: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.29. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire•3 months ago
Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Moffitt Cancer Center collaborators to present next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases.
- Zacks•4 months ago
Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher
Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Associated Press•6 months ago
Atara Biotherapeutics: 2Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...
